Table Omnitus n / pl / rev modif.vysv. 50mg 10 pc

$5.46

Table Omnitus n / pl / rev modif.vysv. 50mg 10 pc

Quantity:

SKU: 0696964067 Categories: , , Tags: ,

Description

Composition
Active substance:
1 c modified-release tablet, film-coated 50mg comprises:
Butamirata citrate 50 mg ;.
Excipients:
Lactose monohydrate – 230.5 mg Hypromellose – 85.0 mg Talc – 10.0 mg Magnesium stearate – 12.0 mg, colloidal silicon dioxide, anhydrous – 6.0 mg Povidone – 1.5 mg, the composition of the shell : hypromellose – 5,305 mg talc – 4,950 mg, ethylcellulose – 3.183 mg macrogol – 1,273 mg, titanium dioxide – 1,061 mg, dye Ponceau [Ponceau 4R] [E 124] – 2,122 mg, brown varnish (dye sunset yellow [E110 ] azorubin dye [E122], black dye [E151]) – 0.106 mg.
Description:
Round biconvex tablets, film-coated deep red color. The cross-sectional core of a white or nearly white.
Product form:
C modified release tablets, film-coated 50mg
10 tablets in a blister made of PVC / AL. 1 blister together with instructions for use placed into cardboard pack.
Contraindications
Increased sensitivity to the drug, pregnancy (I term), lactation, children under 6 years of age – 20 mg tablets, children up to 18 years – 50 mg tablets. Lactose intolerance, lactase deficiency, glucose-galactose malabsorption (formulation contains lactose).
Dosage
50 mg
Indications
Dry cough from any cause (for colds, flu, whooping cough and other conditions). cough suppression in the preoperative and postoperative period, during surgery, bronchoscopy.
Interaction with other drugs
Any drug interactions are not described for butamirata. During the period of treatment with the drug is not recommended to drink alcohol, and drugs that suppress the central nervous system (hypnotics, neuroleptics, tranquilizers, etc..).
Overdose
Symptoms: dizziness, drowsiness, nausea, vomiting, diarrhea, incoordination, decreased blood pressure.
Treatment: gastric lavage; activated charcoal, saline laxatives, symptomatic therapy (if indicated).
pharmachologic effect
Pharmacological group:
Antitussive central action.
Pharmacological properties:
Antitussive, expectorant provides moderate bronchodilatory and anti-inflammatory effect.
Butamirata citrate is neither chemical nor farmakologicheski alkaloidami akin to opium and has a direct effect on the cough center, improves spirometry and blood oxygenation.
Pharmacodynamics:
Butamirata, Omnitus® active substance preparation is a centrally acting antitussive. Either chemically or farmakologicheski not apply to alkaloidam opium. It does not produce dependence or addiction. Suppresses cough, having a direct effect on the cough center. It has bronchodilatory effect (expands bronchi). It helps to alleviate respiratory spirometry improves (reduces airway resistance) and blood oxygenation (saturates the blood with oxygen).
Pharmacokinetics:
Absorption – high. After oral syrup in a dose containing 150 mg butamirata citrate maximum plasma concentration of the main metabolite (2-phenylbutyric acid) was observed after 1.5 hours and is 6.4 ug / ml, when receiving tablets with modified release (50 mg), respectively, – 9 h and 1.4 ug / ml. The half syrup – 6 hours, for tablets – 13 hours no cumulative effect.. Butamirata tsitrat rapidly hydrolyzed in plazme 2-fenilmaslyanuyu acid and dietilaminoetoksietanol. Oba these metabolita, obladayuschie takzhe antitussive effect, largely bound to plasma proteins, which explains their long presence in the plasma. Subsequently major metabolite 2-fenilmaslyanaya kislota 14C is oxidized to p-hydroxy-2-phenylbutyric acid. All three metabolita pochkami output, wherein the acidic metabolity svyazany mainly with glucuronic acid.
Pregnancy and breast-feeding
There are no data on the safety of drugs in pregnancy, and it passes through the placental barrier. Use of the drug in the I trimester of pregnancy is contraindicated. In II and III trimester of pregnancy, the use of the drug may be the case if the expected benefit to the mother outweighs the potential risk to the fetus. It is not known whether the active substance penetrates the drug or its metabolites in breast milk, therefore the use of the drug in the breastfeeding period is not recommended.
Conditions of supply of pharmacies
Without recipe.
side effects
Classification of the incidence of adverse reactions: very common (> 1/10), common (
From the digestive system: rarely – nausea, diarrhea.
Allergic reactions: seldom – skin rash, itching, hives.
special instructions
Omnitus® can cause dizziness and drowsiness, so the period of treatment must be careful when driving and performing other potentially hazardous activities that require high concentration and psychomotor speed reactions.
Storage conditions
Stored in a dry place, protected from light, at a temperature from 15 to 25 ° C.
Dosing and Administration
Inside. Tablets are taken before a meal, without chewing.
Adults: 1 tablet every 8-12 hours
If cough persists for more than 5 days after the start of treatment, you should consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

STADA

There are no reviews yet.

Add your review